JP2005514441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514441A5 JP2005514441A5 JP2003559507A JP2003559507A JP2005514441A5 JP 2005514441 A5 JP2005514441 A5 JP 2005514441A5 JP 2003559507 A JP2003559507 A JP 2003559507A JP 2003559507 A JP2003559507 A JP 2003559507A JP 2005514441 A5 JP2005514441 A5 JP 2005514441A5
- Authority
- JP
- Japan
- Prior art keywords
- phenylphenylmethyl
- oxopropyl
- carboxy
- amino
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 3
- 229960004699 valsartan Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- -1 3- carboxy-1-oxopropyl Chemical group 0.000 claims 4
- ZBSFEPOXERUZFE-SFHVURJKSA-N (2R)-4-amino-2-methyl-2-[(4-phenylphenyl)methyl]butanoic acid Chemical compound C1(=CC=CC=C1)C1=CC=C(C=C1)C[C@@](C(=O)O)(CCN)C ZBSFEPOXERUZFE-SFHVURJKSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UEBQNXUHSKFIIR-FQEVSTJZSA-N ethyl (2R)-4-amino-2-methyl-2-[(4-phenylphenyl)methyl]butanoate Chemical compound C(C)OC([C@](CCN)(C)CC1=CC=C(C=C1)C1=CC=CC=C1)=O UEBQNXUHSKFIIR-FQEVSTJZSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XAIFNLJOYACUNR-IBGZPJMESA-N CC(C)[C@@H](C(O)=O)N(Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1)C(C)=O Chemical compound CC(C)[C@@H](C(O)=O)N(Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1)C(C)=O XAIFNLJOYACUNR-IBGZPJMESA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34966002P | 2002-01-17 | 2002-01-17 | |
| US60/349,660 | 2002-01-17 | ||
| PCT/EP2003/000415 WO2003059345A1 (en) | 2002-01-17 | 2003-01-16 | Pharmaceutical compositions comprising valsartan and nep inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116928A Division JP2011207898A (ja) | 2002-01-17 | 2011-05-25 | バルサルタンおよびｎｅｐ阻害剤を含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005514441A JP2005514441A (ja) | 2005-05-19 |
| JP2005514441A5 true JP2005514441A5 (enExample) | 2011-08-04 |
| JP4820056B2 JP4820056B2 (ja) | 2011-11-24 |
Family
ID=23373410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003559507A Expired - Lifetime JP4820056B2 (ja) | 2002-01-17 | 2003-01-16 | バルサルタンおよびｎｅｐ阻害剤を含む医薬組成物 |
| JP2011116928A Withdrawn JP2011207898A (ja) | 2002-01-17 | 2011-05-25 | バルサルタンおよびｎｅｐ阻害剤を含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116928A Withdrawn JP2011207898A (ja) | 2002-01-17 | 2011-05-25 | バルサルタンおよびｎｅｐ阻害剤を含む医薬組成物 |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1467728B1 (enExample) |
| JP (2) | JP4820056B2 (enExample) |
| KR (2) | KR100984939B1 (enExample) |
| CN (2) | CN1615134A (enExample) |
| AT (1) | ATE370732T1 (enExample) |
| AU (1) | AU2003206738C1 (enExample) |
| BE (1) | BE2016C025I2 (enExample) |
| BR (2) | BR122018015003B8 (enExample) |
| CA (1) | CA2472399C (enExample) |
| CO (1) | CO5600999A2 (enExample) |
| CY (2) | CY1106959T1 (enExample) |
| DE (1) | DE60315795T2 (enExample) |
| DK (1) | DK1467728T3 (enExample) |
| EC (1) | ECSP045190A (enExample) |
| ES (1) | ES2290429T3 (enExample) |
| FR (1) | FR16C0019I2 (enExample) |
| HU (1) | HUS1600024I1 (enExample) |
| IL (2) | IL162661A0 (enExample) |
| LU (1) | LU93074I2 (enExample) |
| MX (1) | MXPA04006917A (enExample) |
| NL (1) | NL300811I2 (enExample) |
| NO (2) | NO333191B1 (enExample) |
| NZ (1) | NZ533968A (enExample) |
| PL (1) | PL212318B1 (enExample) |
| PT (1) | PT1467728E (enExample) |
| RU (1) | RU2334513C3 (enExample) |
| SI (1) | SI1467728T1 (enExample) |
| WO (1) | WO2003059345A1 (enExample) |
| ZA (1) | ZA200405117B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005256634B2 (en) * | 2004-06-23 | 2010-12-09 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists |
| CA2592091A1 (en) | 2004-12-24 | 2006-06-29 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| WO2007045663A2 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) * | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
| ES2602566T3 (es) | 2007-01-12 | 2017-02-21 | Novartis Ag | Proceso para preparar ácido 5-bifenil-4-amino-2-metil pentanoico |
| GB0708507D0 (en) | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
| PL2295035T3 (pl) * | 2007-11-06 | 2016-11-30 | Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep) | |
| CN101774941A (zh) * | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | 2-酰基氨基-3-联苯基丙酸的制备及拆分方法 |
| ES2602902T3 (es) | 2009-05-28 | 2017-02-22 | Novartis Ag | Derivados aminopropiónicos sustituidos como inhibidores de neprilisina |
| CN102448928B (zh) | 2009-05-28 | 2014-10-01 | 诺华股份有限公司 | 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| KR101476937B1 (ko) | 2010-08-23 | 2014-12-24 | 노파르티스 아게 | Ｎｅｐ 억제제의 제조를 위한 중간체의 제조 방법 |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| JP6482462B2 (ja) * | 2012-08-24 | 2019-03-13 | ノバルティス アーゲー | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| TR201808541T4 (tr) | 2013-02-14 | 2018-07-23 | Novartis Ag | Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri. |
| EP2956445A1 (en) | 2013-02-14 | 2015-12-23 | Novartis AG | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
| CN104230865B (zh) * | 2013-06-13 | 2018-01-09 | 上海翰森生物医药科技有限公司 | 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途 |
| EP3038653A1 (en) | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
| HUE064634T2 (hu) | 2013-08-26 | 2024-04-28 | Novartis Ag | Kardiovaszkuláris betegségek kezelése |
| WO2016029828A1 (zh) * | 2014-08-27 | 2016-03-03 | 上海翰森生物医药科技有限公司 | AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用 |
| WO2016037098A1 (en) * | 2014-09-04 | 2016-03-10 | Concert Pharmaceuticals, Inc. | Deuterated sacubitril |
| WO2016037552A1 (zh) * | 2014-09-09 | 2016-03-17 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| CN105503760A (zh) * | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
| WO2016074651A1 (en) | 2014-11-14 | 2016-05-19 | Zentiva, K.S. | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 |
| WO2016086798A1 (zh) * | 2014-12-03 | 2016-06-09 | 上海翰森生物医药科技有限公司 | Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用 |
| SI3229799T1 (sl) * | 2014-12-08 | 2019-03-29 | Crystal Pharmatech Co., Ltd. | Kristalinične oblike trinatrijevega supramolekularnega kompleksa, ki obsega valsartan in AHU-377, ter njihovi postopki |
| CN105693543B (zh) * | 2014-12-15 | 2018-08-10 | 四川海思科制药有限公司 | 沙库比曲类衍生物、其药物组合物、制备方法及用途 |
| CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
| CN106138069A (zh) * | 2015-04-21 | 2016-11-23 | 刘春丽 | 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷 |
| JP6576469B2 (ja) | 2015-05-11 | 2019-09-18 | ノバルティス アーゲー | 心不全の治療のためのサクビトリル−バルサルタンの用量計画 |
| JP2018516267A (ja) | 2015-05-29 | 2018-06-21 | ノバルティス アーゲー | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| CN106397248A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种lcz696结晶粉末及其制备方法 |
| EP3355880A1 (en) | 2015-08-28 | 2018-08-08 | Novartis AG | New use |
| WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| CN105348209B (zh) * | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
| WO2017097275A1 (en) | 2015-12-11 | 2017-06-15 | Zentiva, K.S. | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method |
| HK1256865A1 (zh) | 2016-02-03 | 2019-10-04 | Novartis Ag | 有机化合物的盖伦制剂 |
| WO2017134600A1 (en) | 2016-02-03 | 2017-08-10 | Novartis Ag | New use of a combination of sacubitril and valsartan |
| FI3524250T3 (fi) | 2016-10-08 | 2025-08-29 | Wuhan Ll Science & Technology Development Co Ltd | Neutraalia endopeptidaasin (nep) estäjää ja atsilsartaaniesterijohdannaista sisältävä farmaseuttinen koostumus ja sen käyttö sydän- ja verisuonitautien hoitoon |
| WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
| US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
| EA202090398A1 (ru) | 2017-07-28 | 2020-05-15 | Синтон Б.В. | Фармацевтическая композиция, включающая сакубитрил и валсартан |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CN110237071B (zh) | 2018-03-09 | 2022-03-22 | 武汉朗来科技发展有限公司 | 药物制剂及其应用 |
| CA3110152A1 (en) | 2018-08-23 | 2020-02-27 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| KR20200020746A (ko) | 2020-02-07 | 2020-02-26 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
| WO2021158084A1 (ko) * | 2020-02-07 | 2021-08-12 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
| KR20210101164A (ko) | 2020-02-07 | 2021-08-18 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
| KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
| KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
| WO2024136185A1 (ko) | 2022-12-20 | 2024-06-27 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물 |
| WO2024136184A1 (ko) | 2022-12-20 | 2024-06-27 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1256692A (en) * | 1991-02-06 | 1992-09-07 | Schering Corporation | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
| US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| CA2168066A1 (en) * | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
| EP1267855A2 (en) * | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Company | Vasopeptidase inhibitors to treat isolated systolic hypertension |
| AU8576801A (en) * | 2000-06-22 | 2002-01-02 | Novartis Ag | Pharmaceutical compositions |
| PE20020613A1 (es) * | 2000-07-19 | 2002-08-07 | Novartis Ag | Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1 |
| US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
-
2003
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 CA CA2472399A patent/CA2472399C/en not_active Expired - Lifetime
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko not_active Ceased
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/en not_active Ceased
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Ceased
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 EP EP03704413A patent/EP1467728B1/en not_active Expired - Lifetime
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
-
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
-
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
-
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
-
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I2/no unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I2/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514441A5 (enExample) | ||
| JP5631053B2 (ja) | 門脈圧亢進症の予防及び／又は治療 | |
| JP4804004B2 (ja) | 関節軟骨細胞外マトリクス分解阻害剤 | |
| KR101715008B1 (ko) | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 | |
| US8343947B2 (en) | Therapeutic treatment | |
| CN1194681C (zh) | 用于抗血栓形成的甘氨酸甜菜碱 | |
| US20080113973A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| JP2005528430A5 (enExample) | ||
| WO2001005394A1 (en) | Agents inhibiting chronic rejection reactions after organ transplantation | |
| JPS63141934A (ja) | ディルチアゼムおよびアンギオテンシン変換酵素阻害剤を含有する医薬組成物 | |
| WO2024173556A3 (en) | Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors | |
| JP2010532348A5 (enExample) | ||
| KR101342716B1 (ko) | 항-혈소판 약물, 영양 및 비타민 보충물로서의 아세틸화된아미노산 | |
| JP2007517911A (ja) | 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法 | |
| JPH0616570A (ja) | 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物 | |
| JP4839309B2 (ja) | 血栓症治療剤 | |
| CN1271283A (zh) | 内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的药物组合物 | |
| US20060160896A1 (en) | Therapeutic treatment | |
| JP2009532494A5 (enExample) | ||
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| Liu et al. | Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats | |
| RU2007169C1 (ru) | Средство, обладающее антигипертензивным действием | |
| JP2003504404A (ja) | 抗虚血薬 | |
| AU2003259261B2 (en) | Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure | |
| JPH09227371A (ja) | 粥状動脈硬化抑制剤 |